{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:31:10Z","timestamp":1784633470599,"version":"3.55.0"},"reference-count":147,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>In the last decade, anti-CD19 CAR-T cell therapy has led to a treatment paradigm shift for B-cell non-Hodgkin lymphomas, first with the approval for relapsed\/refractory (R\/R) large B-cell lymphomas and subsequently for R\/R mantle cell and follicular lymphoma. Many efforts are continuously being made to extend the therapeutic setting in the lymphoma field. Several reports are supporting the safety and efficacy of CAR-T cells in patients with central nervous system disease involvement. Anti-CD30 CAR-T cells for the treatment of Hodgkin lymphoma are in development and early studies looking for the optimal target for T-cell malignancies are ongoing. Anti-CD19\/CD20 and CD19\/CD22 dual targeting CAR-T cells are under investigation in order to increase anti-lymphoma activity and overcome tumor immune escape. Allogeneic CAR product engineering is on the way, representing a rapidly accessible \u2018off-the-shelf\u2019 and potentially more fit product. In the present manuscript, we will focus on recent advances in CAR-T cell therapy for lymphomas, including new settings and future perspectives in the field, reviewing data reported in literature in the last decade up to October 2023.<\/jats:p>","DOI":"10.3390\/cancers16010046","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T03:36:17Z","timestamp":1703129777000},"page":"46","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Chimeric Antigen Receptor-T Cell Therapy for Lymphoma: New Settings and Future Directions"],"prefix":"10.3390","volume":"16","author":[{"given":"Corrado","family":"Benevolo Savelli","sequence":"first","affiliation":[{"name":"Hematology Division, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, C.so Bramante 88, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Clerico","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, C.so Bramante 88, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Botto","sequence":"additional","affiliation":[{"name":"Hematology Division, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, C.so Bramante 88, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Secreto","sequence":"additional","affiliation":[{"name":"Stem Cell Transplant Center, AOU Citt\u00e0 della Salute e della Scienza di Torino, C.so Bramente 88, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Cavallo","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, C.so Bramante 88, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Dellacasa","sequence":"additional","affiliation":[{"name":"Stem Cell Transplant Center, AOU Citt\u00e0 della Salute e della Scienza di Torino, C.so Bramente 88, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5361-5613","authenticated-orcid":false,"given":"Alessandro","family":"Busca","sequence":"additional","affiliation":[{"name":"Stem Cell Transplant Center, AOU Citt\u00e0 della Salute e della Scienza di Torino, C.so Bramente 88, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7299-6770","authenticated-orcid":false,"given":"Benedetto","family":"Bruno","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, C.so Bramante 88, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Freilone","sequence":"additional","affiliation":[{"name":"Hematology Division, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, C.so Bramante 88, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1666-3100","authenticated-orcid":false,"given":"Marco","family":"Cerrano","sequence":"additional","affiliation":[{"name":"Hematology Division, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, C.so Bramante 88, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5127-3653","authenticated-orcid":false,"given":"Mattia","family":"Novo","sequence":"additional","affiliation":[{"name":"Hematology Division, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, C.so Bramante 88, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"New Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy Bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"New Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma (CARTITUDE-1): A Phase 1b\/2 Open-Label Study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.2741\/4780","article-title":"Adoptive Immunotherapy with CAR Modified T Cells in Cancer: Current Landscape and Future Perspectives","volume":"24","author":"Coscia","year":"2019","journal-title":"Front. Biosci.-Landmark"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"102443","DOI":"10.1016\/j.ctrv.2022.102443","article-title":"Treatment Strategies for Patients with Diffuse Large B-Cell Lymphoma","volume":"110","author":"Poletto","year":"2022","journal-title":"Cancer Treat Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"New Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"New Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene Maraleucel for Patients with Relapsed or Refractory Large B-Cell Lymphomas (TRANSCEND NHL 001): A Multicentre Seamless Design Study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-Term Safety and Activity of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1): A Single-Arm, Multicentre, Phase 1-2 Trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_10","unstructured":"(2023, October 10). YESCARTA (Axicabtagene Ciloleucel)|FDA, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/yescarta-axicabtagene-ciloleucel."},{"key":"ref_11","unstructured":"(2023, October 10). Yescarta | European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/yescarta."},{"key":"ref_12","unstructured":"(2023, October 10). BREYANZI (Lisocabtagene Maraleucel)|FDA, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/breyanzi-lisocabtagene-maraleucel."},{"key":"ref_13","unstructured":"(2023, October 10). Breyanzi | European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/breyanzi."},{"key":"ref_14","unstructured":"(2023, October 10). KYMRIAH (Tisagenlecleucel)|FDA, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/kymriah-tisagenlecleucel."},{"key":"ref_15","unstructured":"(2023, October 10). Kymriah | European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kymriah."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"New Engl. J. Med."},{"key":"ref_17","unstructured":"(2023, October 10). TECARTUS (Brexucabtagene Autoleucel)|FDA, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/tecartus-brexucabtagene-autoleucel."},{"key":"ref_18","unstructured":"(2023, October 10). Tecartus|European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tecartus."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"New Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene Maraleucel versus Standard of Care with Salvage Chemotherapy Followed by Autologous Stem Cell Transplantation as Second-Line Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (TRANSFORM): Results from an Interim Analysis of an Open-Label, Randomised, Phase 3 Trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"New Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fimmu.2020.00888","article-title":"The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research into Clinical Practice","volume":"11","author":"Cerrano","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood.2021010930","article-title":"CD19 Target Evasion as a Mechanism of Relapse in Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel","volume":"138","author":"Plaks","year":"2021","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2020007445","article-title":"Tumor Interferon Signaling and Suppressive Myeloid Cells Are Associated with CAR T-Cell Failure in Large B-Cell Lymphoma","volume":"137","author":"Jain","year":"2021","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/trf.14003","article-title":"Autologous Lymphapheresis for the Production of Chimeric Antigen Receptor T Cells","volume":"57","author":"Allen","year":"2017","journal-title":"Transfusion"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/bjh.18831","article-title":"Risk Factors for CAR-T Cell Manufacturing Failure among DLBCL Patients: A Nationwide Survey in Japan","volume":"202","author":"Jo","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_28","first-page":"40","article-title":"Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed\/Refractory (R\/R) Indolent Non-Hodgkin Lymphoma (INHL)","volume":"136","author":"Jacobson","year":"2020","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"10380","DOI":"10.1182\/blood-2022-156120","article-title":"3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed\/Refractory (R\/R) Indolent Non-Hodgkin Lymphoma (INHL)","volume":"140","author":"Neelapu","year":"2022","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/14737140.2023.2171994","article-title":"A 24-Month Updated Analysis of the Comparative Effectiveness of ZUMA-5 (Axi-Cel) vs. SCHOLAR-5 External Control in Relapsed\/Refractory Follicular Lymphoma","volume":"23","author":"Palomba","year":"2023","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1182\/blood-2022-158024","article-title":"Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed\/Refractory Follicular Lymphoma (r\/r FL) Treated with Tisagenlecleucel in the Elara Trial","volume":"140","author":"Dreyling","year":"2022","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1182\/bloodadvances.2022008150","article-title":"Efficacy Comparison of Tisagenlecleucel vs Usual Care in Patients with Relapsed or Refractory Follicular Lymphoma","volume":"6","author":"Salles","year":"2022","journal-title":"Blood Adv."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/hon.3196_LBA4","article-title":"TRANSCEND FL: PHASE 2 STUDY RESULTS OF LISOCABTAGENE MARALEUCEL (LISO-CEL) IN PATIENTS (PTS) WITH RELAPSED\/REFRACTORY (R\/R) FOLLICULAR LYMPHOMA (FL)","volume":"41","author":"Morschhauser","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_34","unstructured":"(2023, October 10). Study Details | Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants with Relapsed\/Refractory Follicular Lymphoma|ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05371093."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S1470-2045(21)00648-3","article-title":"CAR T-Cell Therapy for Indolent Lymphoma: A New Treatment Paradigm?","volume":"23","author":"Holtzman","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e004128","DOI":"10.1136\/jitc-2021-004128","article-title":"CD19-Directed Chimeric Antigen Receptor T Cell Therapy in Waldenstr\u00f6m Macroglobulinemia: A Preclinical Model and Initial Clinical Experience","volume":"10","author":"Qualls","year":"2022","journal-title":"J. Immunother Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e68877ca","DOI":"10.1097\/01.HS9.0000971284.68877.ca","article-title":"P1097: CD20 CAR-T THERAPY WITH MB-106 FOR BTK INHIBITOR-REFRACTORY WALDENSTR\u00d6M MACROGLOBULINEMIA (WM)\/LYMPHOPLASMACYTIC LYMPHOMA (LPL)\u2014SINGLE INSTITUTION STUDY","volume":"7","author":"Shadman","year":"2023","journal-title":"Hemasphere"},{"key":"ref_38","unstructured":"(2023, October 10). Study Details | Study of Brexucabtagene Autoleucel in Adults with Rare B-Cell Malignancies|ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05537766."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41375-021-01345-8","article-title":"Long-Term Activity of Tandem CD19\/CD20 CAR Therapy in Refractory\/Relapsed B-Cell Lymphoma: A Single-Arm, Phase 1-2 Trial","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Relapsed B Cell Malignancies: A Phase 1 Dose Escalation and Expansion Trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/ajh.26718","article-title":"Long-Term Outcomes and Predictors of Early Response, Late Relapse, and Survival for Patients Treated with Bispecific LV20.19 CAR T-Cells","volume":"97","author":"Zurko","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood.2019000017","article-title":"Efficacy and Safety of CAR19\/22 T-Cell Cocktail Therapy in Patients with Refractory\/Relapsed B-Cell Malignancies","volume":"135","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"664421","DOI":"10.3389\/fonc.2021.664421","article-title":"A Prospective Investigation of Bispecific CD19\/22 CAR T Cell Therapy in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1158\/2326-6066.CIR-20-0675","article-title":"CD19\/CD22 Dual-Targeted CAR T-Cell Therapy for Relapsed\/Refractory Aggressive B-Cell Lymphoma: A Safety and Efficacy Study","volume":"9","author":"Wei","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T Cells with Dual Targeting of CD19 and CD22 in Adult Patients with Recurrent or Refractory B Cell Malignancies: A Phase 1 Trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1182\/blood.2021014738","article-title":"Safety and Efficacy of Tisagenlecleucel in Primary CNS Lymphoma: A Phase 1\/2 Clinical Trial","volume":"139","author":"Frigault","year":"2022","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1097\/01.HS9.0000848696.94414.98","article-title":"P1460: SAFETY AND EFFICACY FINDINGS OF AUTO1, A FAST-OFF RATE CD19 CAR, IN RELAPSED\/REFRACTORY PRIMARY CNS LYMPHOMA","volume":"6","author":"Roddie","year":"2022","journal-title":"Hemasphere"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.3389\/fonc.2020.01306","article-title":"CAR T-Cell Therapy Is Effective but Not Long-Lasting in B-Cell Lymphoma of the Brain","volume":"10","author":"Li","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_50","first-page":"1","article-title":"Anti-CD30 Chimeric Antigen Receptor T Cell Therapy for Relapsed\/Refractory CD30+ Lymphoma Patients","volume":"10","author":"Wang","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and Immunological Responses after CD30-Specific Chimeric Antigen Receptor-Redirected Lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood-2019-129559","article-title":"Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed\/Refractory T-Cell Malignancies","volume":"134","author":"Hill","year":"2019","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-023-00822-w","article-title":"Allogenic and Autologous Anti-CD7 CAR-T Cell Therapies in Relapsed or Refractory T-Cell Malignancies","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1182\/blood-2021-146236","article-title":"Phase 1 Study of CD37-Directed CAR T Cells in Patients with Relapsed or Refractory CD37+ Hematologic Malignancies","volume":"138","author":"Frigault","year":"2021","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/hon.3163_44","article-title":"FIRST IN HUMAN STUDY OF AUTO4, A TRBC1-TRAGETTING CART T CELL THERAPY IN RELAPSED\/REFRACTORY TRBC1-POSITIVE PERIPHERAL T-CELL LYMPHOMA","volume":"41","author":"Cwynarski","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1182\/blood-2021-146038","article-title":"ALPHA Study: ALLO-501 Produced Deep and Durable Responses in Patients with Relapsed\/Refractory Non-Hodgkin\u2019s Lymphoma Comparable to Autologous CAR T","volume":"138","author":"Neelapu","year":"2021","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/hon.3163_48","article-title":"DURABLES RESPONSES WITH ANTI-CD19 ALLOGENEIC CAR T ALLO-501\/501A IN PHASE 1 TRIALS OF RELAPSED\/REFRACTORY LARGE B-CELL LYMPHOMA (R\/R LBCL)","volume":"41","author":"Heslop","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.1200\/JCO.2021.39.15_suppl.7516","article-title":"Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic, off-the-Shelf CD19-Targeting CAR-T Product, in Relapsed\/Refractory (r\/r) CD19+ NHL","volume":"39","author":"Shah","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"10303","DOI":"10.1182\/blood-2022-166432","article-title":"CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R\/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study","volume":"140","author":"McGuirk","year":"2022","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/01.HS9.0000843940.96598.e2","article-title":"S262: The COBALT-LYM Study of CTX130: A Phase 1 Dose Escalation Study of Cd70-Targeted Allogeneic CRISPR-Cas9\u2013Engineered Car T Cells In Patients With Relapsed\/Refractory (R\/R) T-Cell Malignancies","volume":"6","author":"Iyer","year":"2022","journal-title":"Hemasphere"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/01.HS9.0000848676.15840.df","article-title":"P1455: First-In-Human Trial Of CB-010, A Crispr-Edited Allogeneic Anti-Cd19 Car-T Cell Therapy with A Pd-1 Knock Out, In Patients with Relapsed Or Refractory B Cell Non-Hodgkin Lymphoma (ANTLER Study)","volume":"6","author":"Nastoupil","year":"2022","journal-title":"Hemasphere"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","article-title":"Genetically Modified CD7-Targeting Allogeneic CAR-T Cell Therapy with Enhanced Efficacy for Relapsed\/Refractory CD7-Positive Hematological Malignancies: A Phase I Clinical Study","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/blood-2022-160244","article-title":"CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells (CD30.CAR EBVSTs) Provide a Safe and Effective Off-the-Shelf Therapy for Patients with CD30-Positive Lymphoma","volume":"140","author":"Quach","year":"2022","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/hon.3164_389","article-title":"First in Human Data of NKX019, an Allogeneic CAR NK for the Treatment of Relapsed\/Refractory (R\/R) B-Cell Malignancies","volume":"41","author":"Dickinson","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"7541","DOI":"10.1200\/JCO.2021.39.15_suppl.7541","article-title":"Preliminary Results of a Phase I Trial of FT516, an off-the-Shelf Natural Killer (NK) Cell Therapy Derived from a Clonal Master Induced Pluripotent Stem Cell (IPSC) Line Expressing High-Affinity, Non-Cleavable CD16 (HnCD16), in Patients (Pts) with Relapsed\/Refractory (R\/R) B-Cell Lymphoma (BCL)","volume":"39","author":"Strati","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1182\/blood-2022-167194","article-title":"Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, IPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed\/Refractory B-Cell Malignancies","volume":"140","author":"Mehta","year":"2022","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"7529","DOI":"10.1200\/JCO.2023.41.16_suppl.7529","article-title":"AB-101, an Allogeneic, Non\u2013Genetically Modified, Natural Killer (NK) Cell Therapy, Evaluated as Monotherapy or in Combination with Rituximab in R\/R Non-Hodgkin Lymphoma","volume":"41","author":"Khanal","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11060-006-9165-6","article-title":"Relapse of Primary Central Nervous System Lymphoma: Clinical Features, Outcome and Prognostic Factors","volume":"80","author":"Jahnke","year":"2006","journal-title":"J. Neurooncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3109\/10428199909058415","article-title":"Isolated Central Nervous System Relapse in Aggressive Non-Hodgkin\u2019s Lymphoma: The Bologna Experience","volume":"32","author":"Zinzani","year":"1999","journal-title":"Leuk. Lymphoma"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.clml.2020.10.015","article-title":"Primary Central Nervous System Lymphoma: Evolving Biologic Insights and Recent Therapeutic Advances","volume":"21","author":"Chihara","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","article-title":"Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies","volume":"183","author":"Parker","year":"2020","journal-title":"Cell"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric Antigen Receptor\u2013Modified T Cells for Acute Lymphoid Leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"New Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"eaag2196","DOI":"10.1126\/scitranslmed.aag2196","article-title":"Reporter Gene Imaging of Targeted T Cell Immunotherapy in Recurrent Glioma","volume":"9","author":"Keu","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMc1704610","article-title":"Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma","volume":"377","author":"Abramson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.mayocp.2019.09.006","article-title":"Axicabtagene Ciloleucel Chimeric Antigen Receptor T Cell Therapy in Lymphoma with Secondary Central Nervous System Involvement","volume":"94","author":"Novo","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR T-Cell Therapy in Secondary CNS Lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41409-020-01099-4","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy for Relapsed\/Refractory Secondary CNS Non-Hodgkin Lymphoma: Comparable Outcomes and Toxicities, but Shorter Remissions May Warrant Alternative Consolidative Strategies?","volume":"56","author":"Ghafouri","year":"2021","journal-title":"Bone Marrow Transpl."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1182\/bloodadvances.2021005292","article-title":"CAR T-Cell Therapy for Secondary CNS DLBCL","volume":"5","author":"Ahmed","year":"2021","journal-title":"Blood Adv."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood-2019-129097","article-title":"Experience with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium","volume":"134","author":"Bennani","year":"2019","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1182\/bloodadvances.2020004106","article-title":"CD19-Directed CAR T-Cell Therapy for Treatment of Primary CNS Lymphoma","volume":"5","author":"Siddiqi","year":"2021","journal-title":"Blood Adv."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1182\/blood.2021012932","article-title":"CAR T-Cell Therapy in Primary Central Nervous System Lymphoma: The Clinical Experience of the French LOC Network","volume":"139","author":"Alcantara","year":"2022","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/bloodadvances.2022008525","article-title":"Toxicity and Efficacy of CAR T-Cell Therapy in Primary and Secondary CNS Lymphoma: A Meta-Analysis of 128 Patients","volume":"7","author":"Cook","year":"2023","journal-title":"Blood Adv."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1182\/bloodadvances.2023010336","article-title":"Real-World Results of CAR T-Cell Therapy for Large B-Cell Lymphoma with CNS Involvement: A GLA\/DRST Study","volume":"7","author":"Ayuk","year":"2023","journal-title":"Blood Adv."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41408-021-00523-2","article-title":"Sequential CD19\/22 CAR T-Cell Immunotherapy Following Autologous Stem Cell Transplantation for Central Nervous System Lymphoma","volume":"11","author":"Wu","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/bloodadvances.2022008031","article-title":"CAR T-Cell Therapy for Mantle Cell Lymphoma with Central Nervous System Relapse","volume":"7","author":"Vu","year":"2023","journal-title":"Blood Adv."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene Ciloleucel as First-Line Therapy in High-Risk Large B-Cell Lymphoma: The Phase 2 ZUMA-12 Trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"doi","DOI":"10.1182\/hem.V20.4.2023414","article-title":"Will CAR T-Cell Therapy Be the Preferred Modality in Frontline Treatment of Large B-Cell Lymphoma?","volume":"20","author":"Nastoupil","year":"2023","journal-title":"Hematologist"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/ajh.26301","article-title":"Efficacy and Safety of CD19-Directed CAR-T Cell Therapies in Patients with Relapsed\/Refractory Aggressive B-Cell Lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND Trials","volume":"96","author":"Westin","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T Cells Expressing CD19\/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1146\/annurev-med-042921-024719","article-title":"Multispecific CAR T Cells Deprive Lymphomas of Escape via Antigen Loss","volume":"74","author":"Furqan","year":"2023","journal-title":"Annu. Rev. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fonc.2019.00146","article-title":"Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies","volume":"9","author":"Shah","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","article-title":"The Regulation and Function of CD20: An \u201cEnigma\u201d of B-Cell Biology and Targeted Therapy","volume":"105","author":"Pavlasova","year":"2020","journal-title":"Haematologica"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3389\/fimmu.2011.00096","article-title":"Regulation of B Cell Functions by the Sialic Acid-Binding Receptors Siglec-G and CD22","volume":"2","author":"Jellusova","year":"2012","journal-title":"Front. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"7046","DOI":"10.1158\/1078-0432.CCR-19-1337","article-title":"Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19","volume":"25","author":"Scarfo","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-017-0488-x","article-title":"T Cells Bearing Anti-CD19 and\/or Anti-CD38 Chimeric Antigen Receptors Effectively Abrogate Primary Double-Hit Lymphoma Cells","volume":"10","author":"Mihara","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s12015-019-09948-6","article-title":"Targeting Two Antigens Associated with B-ALL with CD19-CD123 Compound Car T Cell Therapy","volume":"16","author":"Yan","year":"2020","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Golubovskaya, V., Zhou, H., Li, F., Valentine, M., Sun, J., Berahovich, R., Xu, S., Quintanilla, M., Ma, M.C., and Sienkiewicz, J. (2021). Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma. Cancers, 13.","DOI":"10.3390\/cancers13050981"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"640166","DOI":"10.3389\/fonc.2021.640166","article-title":"Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL","volume":"11","author":"Meng","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"eabc6401","DOI":"10.1126\/scitranslmed.abc6401","article-title":"Trispecific CD19-CD20-CD22-Targeting DuoCAR-T Cells Eliminate Antigen-Heterogeneous B Cell Tumors in Preclinical Models","volume":"13","author":"Schneider","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_104","first-page":"2470","article-title":"Dual Targeting of CD19 and CD22 with Bicistronic CAR-T Cells in Patients with Relapsed\/Refractory Large B-Cell Lymphoma","volume":"141","author":"Roddie","year":"2023","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin\u2019s Lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin\u2019s Lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"LBA4","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4","article-title":"SWOG S1826, a Randomized Study of Nivolumab(N)-AVD versus Brentuximab Vedotin(BV)-AVD in Advanced Stage (AS) Classic Hodgkin Lymphoma (HL)","volume":"41","author":"Herrera","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/bloodadvances.2021005385","article-title":"Pretherapy Metabolic Tumor Volume Is Associated with Response to CD30 CAR T Cells in Hodgkin Lymphoma","volume":"6","author":"Voorhees","year":"2022","journal-title":"Blood Adv."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1182\/blood-2019-122846","article-title":"Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed\/Refractory Hodgkin Lymphoma","volume":"134","author":"Voorhees","year":"2019","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1186\/s13287-021-02595-0","article-title":"CAR-T Cell Therapy in T-Cell Malignancies: Is Success a Low-Hanging Fruit?","volume":"12","author":"Rahbarizadeh","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/35105066","article-title":"Cytokines and Immunodeficiency Diseases","volume":"1","author":"Leonard","year":"2001","journal-title":"Nat. Rev. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1038\/s41375-018-0285-8","article-title":"CAR T-Cells for T-Cell Malignancies: Challenges in Distinguishing between Therapeutic, Normal, and Neoplastic T-Cells","volume":"32","author":"Alcantara","year":"2018","journal-title":"Leukemia"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u201coff-the-Shelf\u201d Fratricide-Resistant CAR-T for the Treatment of T Cell Hematologic Malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of Resistance to Chimeric Antigen Receptor T Cell Therapy by Transduction of a Single Leukemic B Cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"20406207221143025","DOI":"10.1177\/20406207221143025","article-title":"Current State of CAR-T Therapy for T-Cell","volume":"13","author":"Luo","year":"2022","journal-title":"Ther. Adv. Hematol."},{"key":"ref_116","first-page":"321","article-title":"Naturally Selected CD7 CAR-T Therapy without Genetic Manipulations for T-ALL\/LBL: First-in-Human Phase 1 Clinical Trial","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1158\/1078-0432.CCR-21-4097","article-title":"Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-Cell Therapy for Patients with Relapsed and Refractory T-Cell Acute Lymphoblastic Leukemia\/Lymphoma","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial","volume":"39","author":"Pan","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood-2019-122789","article-title":"First-in-Human CD4 CAR Clinical Trial on Peripheral T-Cell Lymphoma","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1182\/blood-2018-99-116741","article-title":"Anti-CD30 Chimeric Antigen Receptor T Cell Therapy for CD30+ Relapsed\/Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients","volume":"132","author":"Wang","year":"2018","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1182\/bloodadvances.2020003218","article-title":"Long-Term Remission in Multiply Relapsed Enteropathy-Associated T-Cell Lymphoma Following CD30 CAR T-Cell Therapy","volume":"4","author":"Voorhees","year":"2020","journal-title":"Blood Adv."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","article-title":"Targeting the T Cell Receptor \u03b2-Chain Constant Region for Immunotherapy of T Cell Malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat. Med."},{"key":"ref_123","unstructured":"(2023, October 11). Phase I\/II Study Evaluating AUTO4 in Patients with TRBC1 Positive T Cell Lymphoma\u2014Full Text View\u2014ClinicalTrials.Gov, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03590574."},{"key":"ref_124","unstructured":"(2023, October 11). Study Details | Anti-TRBC1 CAR-T Cell Therapy in Patients with TRBC1 Positive T Cell Malignancies | ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04828174."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u201cOff-the-Shelf\u201d Allogeneic CAR T Cells: Development and Challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"915342","DOI":"10.3389\/fphar.2022.915342","article-title":"CAR T-Cell Therapies in Italy: Patient Access Barriers and Recommendations for Health System Solutions","volume":"13","author":"Jommi","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Chen, Y.J., Abila, B., and Mostafa Kamel, Y. (2023). CAR-T: What Is Next?. Cancers, 15.","DOI":"10.3390\/cancers15030663"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"887866","DOI":"10.3389\/fimmu.2022.887866","article-title":"Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed\/Refractory DLBCL","volume":"13","author":"Jeyakumar","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Sheikh, S., Migliorini, D., and Lang, N. (2022). CAR T-Based Therapies in Lymphoma: A Review of Current Practice and Perspectives. Biomedicines, 10.","DOI":"10.3390\/biomedicines10081960"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11864-021-00920-6","article-title":"Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma","volume":"23","author":"Khurana","year":"2022","journal-title":"Curr. Treat Options Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter Study of Banked Third-Party Virus-Specific T Cells to Treat Severe Viral Infections after Hematopoietic Stem Cell Transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"key":"ref_133","first-page":"2956","article-title":"Infusion of Donor-Derived CD19-Redirected Virus-Specific T Cells for B-Cell Malignancies Relapsed after Allogeneic Stem Cell Transplant: A Phase 1 Study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular Remission of Infant B-ALL after Infusion of Universal TALEN Gene-Edited CAR T Cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"New Engl. J. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ymthe.2017.12.001","article-title":"Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation","volume":"26","author":"Capsomidis","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Sabbah, M., Jondreville, L., Lacan, C., Norol, F., Vieillard, V., Roos-Weil, D., and Nguyen, S. (2022). CAR-NK Cells: A Chimeric Hope or a Promising Therapy?. Cancers, 14.","DOI":"10.3390\/cancers14153839"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3389\/fimmu.2018.00283","article-title":"Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer","volume":"9","author":"Mehta","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Chen, Y., Yu, Z., Tan, X., Jiang, H., Xu, Z., Fang, Y., Han, D., Hong, W., Wei, W., and Tu, J. (2021). CAR-Macrophage: A New Immunotherapy Candidate against Solid Tumors. Biomed. Pharmacother., 139.","DOI":"10.1016\/j.biopha.2021.111605"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1200\/JCO.2022.40.16_suppl.2533","article-title":"A Phase 1, First-in-Human (FIH) Study of the Anti-HER2 CAR Macrophage CT-0508 in Subjects with HER2 Overexpressing Solid Tumors","volume":"40","author":"Reiss","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Gumber, D., and Wang, L.D. (2022). Improving CAR-T Immunotherapy: Overcoming the Challenges of T Cell Exhaustion. EBioMedicine, 77.","DOI":"10.1016\/j.ebiom.2022.103941"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1089\/hum.2021.173","article-title":"Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells","volume":"32","author":"Irving","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41551-023-01013-5","article-title":"A Lentiviral Vector for the Production of T Cells with an Inducible Transgene and a Constitutively Expressed Tumour-Targeting Receptor","volume":"7","author":"Reichenbach","year":"2023","journal-title":"Nat. Biomed. Eng."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"eabh0272","DOI":"10.1126\/scitranslmed.abh0272","article-title":"Deleting DNMT3A in CAR T Cells Prevents Exhaustion and Enhances Antitumor Activity","volume":"13","author":"Prinzing","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 Promotes the Therapeutic Efficacy of CD19-Targeted T Cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR Immune Cells: Design Principles, Resistance and the next Generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/1\/46\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:39:24Z","timestamp":1760132364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/1\/46"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":147,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["cancers16010046"],"URL":"https:\/\/doi.org\/10.3390\/cancers16010046","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]}}}